[36] This randomized, double-blind, placebo-controlled trial found that 200mg of ButyraGen daily led to: Statistically significant reductions in reported belly pain across the study population 20% improvement in women, with even greater benefits in postmenopausal women Improved digestive-related quality of life scores Improvements in both upper and lower digestive comfort Excellent safety profile with no adverse events These studies are explained in greater detail in our article titled " ButyraGen: Next-Generation Prebiotic From NutriScience Innovations That Generates Butyrate Directly " , and demonstrate that ButyraGen provides measurable support for digestive wellness in real-world settings
While these shifts often support metabolic health, they may in some slow motility and predispose the gut to imbalances if not supported
It is often described as a triple-agonist due to its activity on GLP-1, GIP, and glucagon receptors
Prepare them and educate them about this so they dont discontinue in discouragement and you have to start the titration all over again wasting time, money, and negatively impacting the patients health
Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 trial results demonstrating 25% weight loss in half of people with #obesity
.png)
